Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 14Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04148430 2025-11-05

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
62 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡